Condensed Consolidated Statements of Operations and Comprehensive Loss (Unaudited) - USD ($) $ in Thousands	3 Months Ended		9 Months Ended
	Sep. 30, 2024	Sep. 30, 2023	Sep. 30, 2024	Sep. 30, 2023
Revenues	$ 0	$ 0	$ 0	$ 0
Operating expenses:
Research and development	4,932	3,280	13,274	12,855
General and administrative	2,172	2,635	6,629	7,765
Depreciation and amortization	31	32	95	92
Total operating expenses	7,135	5,947	19,998	20,712
Loss from operations	(7,135)	(5,947)	(19,998)	(20,712)
Other income (loss):
(Loss) gain from change in fair value of warrant liability	(1,728)	1	1,423	76
Transaction costs allocated to warrant liabilities	(993)	0	(993)	0
Loss on issuance of warrant liabilities	(847)	0	(847)	0
Other income, net	9	13	31	30
Interest income, net	102	324	503	1,106
Net loss	$ (10,592)	$ (5,609)	$ (19,881)	$ (19,500)
Net loss per common share - basic and diluted (in dollars per share)	$ (2.85)	$ (2.82)	$ (6.83)	$ (9.94)
Weighted average common shares outstanding, basic and diluted (in shares)	3,714,278	1,987,283	2,910,842	1,961,327
Net loss	$ (10,592)	$ (5,609)	$ (19,881)	$ (19,500)
Other comprehensive income (loss):
Foreign currency translation	14	(10)	13	(15)
Comprehensive loss	$ (10,578)	$ (5,619)	$ (19,868)	$ (19,515)